



## Product Information Sheet

### Monoclonal Anti-p16<sup>INK4a/CDKN2</sup>

**Catalogue No.** MA1074

**Immunogen**

Recombinant human p16 protein

**Lot No.** 08A12

**Purification**

Purified by the goat anti-mouse IgG affinity chromatography.

**Clone:** IMD-16

**Ig type:** mouse IgG2a

**Application**

*Western blot*

**Size:** 100µg/vial

At 0.5-1µg/ml with the appropriate system to detect P16 in cells and tissues.

**Specificity**

Human.

*Immunohistochemistry(F)*

No cross reactivity with other proteins.

At 1-2µg/ml to detect P16 in formalin fixed and paraffin embedded tissues.

*Immunocytochemistry*

Suitable

*Other applications have not been tested.*

*Optimal dilutions should be determined by end user.*

**Recommended application**

*Western blot*

*Immunohistochemistry(F)*

*Immunocytochemistry*

**Formulation**

Lyophilized from 1.2% sodium acetate, with 2mg BSA and 0.01mg NaN<sub>3</sub> as preservative.

**Reconstitution**

1.2% sodium acetate or neutral PBS. If 1ml of PBS is used, the antibody concentration will be 100µg/ml.

To reorder contact us at:

**Antagene, Inc.**

**Toll Free: 1(866)964-2589**

**email: Info@antageneinc.com**

**Storage**

At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for longer time.

### BACKGROUND

p16(INK4A), also known as cyclin-dependent kinase inhibitor 2A(CDKN2A), or multiple tumor suppressor 1(MTS1). The p16 gene (CDKN2A) was mapped to 9p21. The p16 gene encodes a negative regulator of the cell cycle. CDKN2 plays an important role during tumorigenesis or tumor progression in a significant proportion of pancreatic adenocarcinomas. Germ-line mutations in the CDKN2A tumor-suppressor gene have been linked to the development of melanoma in some families

**FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE.**

with inherited melanoma.

**REFERENCE**

1. Stone, S.; Jiang, P.; Dayananth, P.; Tavtigian, S. W.; Katcher, H.; Parry, D.; Peters, G.; Kamb, A. : Complex structure and regulation of the p16(MTS1) locus. *Cancer Res.* 55: 2988-2994, 1995.
2. Monzon, J.; Liu, L.; Brill, H.; Goldstein, A. M.; Tucker, M. A.; From, L.; McLaughlin, J.; Hogg, D.; Lassam, N. J. : CDKN2A mutations in multiple primary melanomas. *New Eng. J. Med.* 338: 879-887, 1998.
3. Bartsch, D.; Shevlin, D. W.; Tung, W. S.; Kisker, O.; Wells, S. A., Jr.; Goodfellow, P. J. : Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. *Genes Chromosomes Cancer* 14: 189-195, 1995